The tweet was deleted by the author.
But we saved everything 🙂.
Neumora Therapeutics has announced its financial results for the third quarter of 2026 and shared an update on its business operations.
Further details about the results and the nature of the business update were not disclosed in the announcement tweet.
View post on X Loading...
In previous updates, Neumora Therapeutics shared new data on NMRA-215, a brain-penetrant oral NLRP3 inhibitor in development for obesity treatment. The company has continued to report advancements across its development pipeline. Neumora’s latest announcement follows these earlier disclosures on its research progress.